Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant CAPTEM vs Observation in High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360Phase 2Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- May 2022
- Primary completion
- Mar 2027
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of capecitabine, temozolomide in Pancreatic neuroendocrine tumor (PanNET), sponsored by SWOG Cancer Research Network. Started May 2022; status: recruiting.
02
Drugs
capecitabinetemozolomide
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT05040360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05040360.